Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BNT314 |
Synonyms | |
Therapy Description |
BNT314 (GEN1059) is a bispecific antibody targeting TNFRSF9 (4-1BB) and EpCAM, which potentially induces antitumor immune activity (Ann Oncol (2023) 34 (suppl_2): S619-S650). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BNT314 | BNT 314|BNT-314|GEN1059|GEN 1059|GEN-1059 | TNFRSF9 Antibody 32 | BNT314 (GEN1059) is a bispecific antibody targeting TNFRSF9 (4-1BB) and EpCAM, which potentially induces antitumor immune activity (Ann Oncol (2023) 34 (suppl_2): S619-S650). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06150183 | Phase Ib/II | BNT314 + Pembrolizumab BNT314 | Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors | Recruiting | USA | GBR | ESP | DNK | BEL | 1 |